Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males

This was a double-blind, randomised, placebo-controlled, cross-over study to determine the possible pharmacodynamic and pharmacokinetic interaction of miglitol (CAS 72432-03-2, Bay m 1099) and warfarin sodium (CAS 129-06-6) in healthy volunteers. The study comprised 2 treatment periods of 8 days eac...

Full description

Saved in:
Bibliographic Details
Published inArzneimittel-Forschung Vol. 46; no. 1; p. 41
Main Authors Schall, R, Müller, F O, Hundt, H K, Duursema, L, Groenewoud, G, Middle, M V
Format Journal Article
LanguageEnglish
Published Germany 01.01.1996
Subjects
1-Deoxynojirimycin - analogs & derivatives
Adult
Anticoagulants - adverse effects
Anticoagulants - pharmacokinetics
Anticoagulants - pharmacology
Blood Coagulation - drug effects
Cross-Over Studies
Double-Blind Method
Drug Interactions
Enzyme Inhibitors - adverse effects
Enzyme Inhibitors - pharmacology
Glucosamine - adverse effects
Glucosamine - analogs & derivatives
Glucosamine - pharmacology
Glucosidases - antagonists & inhibitors
Humans
Imino Pyranoses
Male
Stereoisomerism
Warfarin - adverse effects
Warfarin - pharmacokinetics
Warfarin - pharmacology
Online AccessGet more information

Cover

More Information
Summary:This was a double-blind, randomised, placebo-controlled, cross-over study to determine the possible pharmacodynamic and pharmacokinetic interaction of miglitol (CAS 72432-03-2, Bay m 1099) and warfarin sodium (CAS 129-06-6) in healthy volunteers. The study comprised 2 treatment periods of 8 days each, with a medication-free period of 14 days between the 2 treatment periods. The volunteers received medication for 7 days and were assessed over 8 days in both treatment periods. According to the randomisation, the volunteers received either 100 mg of miglitol or matching placebo, 3 times daily during the treatment periods. On Day 4 of each treatment period the volunteers received a single oral dose of 25 mg warfarin sodium together with miglitol or placebo. The effect of miglitol on both the pharmacokinetics and pharmacodynamics (prothrombin time and clotting factor VII activity) of warfarin sodium was investigated. The study results indicate that the concomitant administration of miglitol and warfarin does not affect the pharmacokinetics of R- and S-warfarin, or the pharmacodynamics of warfarin.
ISSN:0004-4172